This report is the second study conducted by Charles River Associates on the role and impact of Health Technology Assessment (HTA) worldwide. The report assesses the performance of the HTA process in 16 countries with mature or developing HTA systems according to international best practice principles.
To read the report, please click below.
CRA's RADAR Insights: Impact of US pricing strategies on orphan drug pricing in Germany - Part 3
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...